Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empowur: Vibegron for Overactive Bladder
NCT03492281Phase 3Completed
- Sponsor
- Urovant Sciences
- Start
- Mar 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of vibegron in overactive bladder (OAB) (3 arms), sponsored by Urovant Sciences. Primary endpoints: Average Number of Micturitions Per 24 Hours at 12 weeks and Average Number of Urge Urinary Incontinence Episodes Per 24 Hours at 12 weeks. Started Mar 2018; status: completed.
02
Drugs
vibegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT03492281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03492281.